in 2018, the first prize of the patent was awarded for the pericallosal synthesis of adenosine arabinose and its analogens by air oxidation
in 2017, it was renamed as xinxiang tuoxin pharmaceutical co., ltd
listed on the neeq in 2014, code 831508
nailabine project was approved as "national torch plan" in 2013.
in 2012, it was renamed as "xinxiang tuoxin biochemical co., ltd."
2010 new 5' -deoxy5-fluorocytoside production process approved as "national torch plan"
in 2008, the foundation of the new plant was laid
in 2007, "new technology of series nucleoside production" won the second prize of national science and technology progress award.
in 2006, the 2' -deoxycytidine pharmaceutical intermediates project was approved as the "national torch plan".
in 2005, "new technology of series nucleoside production" won the first prize of henan province science and technology progress award.
in 2005, the national high-tech industry demonstration project was approved
in 2005, it acquired xinxiang pharmaceutical co., ltd. and introduced canadian xianshi investment company, becoming a sino-foreign joint venture
in 2004, the headquarters building was completed and put into use, with an annual output of 50 tons of uridine pharmaceutical intermediates project approved by the "national torch plan"
in 2001, xinxiang tuoxin company was established and introduced iso9000 quality management system
